Table 2.
Biomarker | Disease | Reference | Number of patients | Age (years) | Male % | Cirrhosis % | White % | Alcohol drinker % | HIV % | Treated % |
---|---|---|---|---|---|---|---|---|---|---|
FibroTest | HCV | Ngo Y, Munteanu M, Messous D, et al14 | 537 | 46 | 60 | 11 | 85 | 14 | 4 | 26 |
HCV | Vergniol J, Foucher J, Terrebonne E, et al16 | 663 | 51 | 53 | 18 | 80 | 0 | 10 | 52 | |
HBV | Ngo Y, Benhamou Y, Thibault V, et al15 | 978 | 41 | 69 | 19 | 26 | 3 | 6 | 60 | |
ALD | Naveau S, Gaude G, Asnacios A, et al7 | 218 | 47 | 78 | 31 | 80 | 100 | 0 | 21* | |
APRI | HCV | Ngo Y, Munteanu M, Messous D, et al14 | 260 | 46 | 60 | 11 | 85 | 14 | 4 | 26 |
HCV | Nunes D, Fleming C, Offner G, et al17 | 303 | 44 | 64 | NA | 49 | 25 | 68 | NA | |
HCV | Vergniol J, Foucher J, Terrebonne E, et al16 | 663 | 51 | 53 | 18 | 80 | 0 | 10 | 52 | |
HBV | Ngo Y, Benhamou Y, Thibault V, et al15 | 978 | 41 | 69 | 19 | 26 | 3 | 6 | 60 | |
ALD | Naveau S, Gaude G, Asnacios A, et al7 | 218 | 47 | 78 | 31 | 80 | 100 | 0 | 21* | |
FIB-4 | HCV | Nunes D, Fleming C, Offner G, et al17 | 303 | 44 | 64 | NA | 49 | 25 | 68 | NA |
HCV | Vergniol J, Foucher J, Terrebonne E, et al16 | 663 | 51 | 53 | 18 | 80 | 0 | 10 | 52 | |
ALD | Naveau S, Gaude G, Asnacios A, et al7 | 218 | 47 | 78 | 31 | 80 | 100 | 0 | 21* | |
HepaScore | ALD | Naveau S, Gaude G, Asnacios A, et al7 | 218 | 47 | 78 | 31 | 80 | 100 | 0 | 21* |
FibroMeter | ALD | Naveau S, Gaude G, Asnacios A, et al7 | 218 | 47 | 78 | 31 | 80 | 100 | 0 | 21* |
ELF | Mixed liver disease | Parkes J, Roderick P, Harris S, et al18 | 457 | 42 | 67 | 17 | 95 | 10 | NA | NA |
FibroScan | HCV | Vergniol J, Foucher J, Terrebonne E, et al16 | 663 | 51 | 53 | 18 | 80 | 0 | 10 | 52 |
Abstinent.
- ALD
alcoholic liver disease
- APRI
aspartate transaminase-platelet ratio index
- HBV
hepatitis B virus
- HCV
hepatitis C virus